Targeting nuclear factor-kappa B to overcome resistance to chemotherapy

Frontiers in Oncology

Volumn 3 MAY, Issue , 2013, Pages

  Godwin, P ^a   Baird, A M ^a   Heavey, S ^a   Barr, M P ^a   O'Byrne, K J ^a   Gately, K ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

Apoptosis; Cancer; Chemotherapy; Cisplatin; NF B; Oncogene; Resistance

Indexed keywords

4 (2 AMINOETHYLAMINO) 1, 8 DIMETHYLIMIDAZO [1, 2 A] QUINOXALINE; 4 (2 AMINOETHYLAMINO) 1,8 DIMETHYLIMIDAZO[1,2 A]QUINOXALINE; BINDARIT; BIOPERINE; BLACK PEPPER EXTRACT; BORTEZOMIB; CARBOPLATIN; CASPASE 8; CD40 ANTIGEN; CISPLATIN; CURCUMIN; CYCLIN D; CYCLIN DEPENDENT KINASE 2; CYCLOHEXIMIDE; CYCLOOXYGENASE 2 INHIBITOR; DOCETAXEL; FAS ANTIGEN; FLICE INHIBITORY PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PARTHENOLIDE; PHOSPHATIDYLETHANOLAMINE BINDING PROTEIN; POLO LIKE KINASE 3; PROTEIN P100; PROTEIN P53; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOTAGMIN I; TEMOZOLOMIDE; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; CANCER CHEMOTHERAPY; CELL PROLIFERATION; DNA DAMAGE; GENE MUTATION; GENETIC TRANSCRIPTION; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; NEOPLASM; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL (TOPIC); PROMOTER REGION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

EID: 84891139838     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00120     Document Type: Review

References (133)

1. Abedini, M. R., Muller, E. J., Brun, J., Bergeron, R., Gray, D. A., and Tsang, B. K. (2008). Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Cancer Res. 68, 4511-4517.
2. Abedini, M. R., Qiu, Q., Yan, X., and Tsang, B. K. (2004). Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Oncogene 23, 6997-7004.
3. Amiri, K. I., Horton, L. W., Lafleur, B. J., Sosman, J. A., and Richmond, A. (2004). Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res. 64, 4912-4918.
4. Annunziata, C. M., Stavnes, H. T., Kleinberg, L., Berner, A., Hernandez, L. F., Birrer, M. J., et al. (2010). Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer. Cancer 116, 3276-3284.
5. Anrather, J., Racchumi, G., and Iadecola, C. (2005). cis-acting, element-specific transcriptional activity of differentially phosphorylated nuclear factor-kappa B. J. Biol. Chem. 280, 244-252.
6. Ariga, A., Namekawa, J., Matsumoto, N., Inoue, J., and Umezawa, K. (2002). Inhibition of tumor necrosis factor-alpha-induced nuclear translocation and activation of NF-kappa B by dehydroxymethylepoxyquinomicin. J. Biol. Chem. 277, 24625-24630.
7. Ashkenazi, A., and Dixit, V. M. (1998). Death receptors: signaling and modulation. Science 281, 1305-1308.
8. Barbie, D. A., Tamayo, P., Boehm, J. S., Kim, S. Y., Moody, S. E., Dunn, I. F., et al. (2009). Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 462, 108-112.
9. Barisic, S., Strozyk, E., Peters, N., Walczak, H., and Kulms, D. (2008). Identification of PP2A as a crucial regulator of the NF-kappaB feedback loop: its inhibition by UVB turns NF-kappaB into a pro-apoptotic factor. Cell Death Differ. 15, 1681-1690.
10. Baritaki, S., Yeung, K., Palladino, M., Berenson, J., and Bonavida, B. (2009). Pivotal roles of snail inhibition and RKIP induction by the proteasome inhibitor NPI-0052 in tumor cell chemoimmunosensitization. Cancer Res. 69, 8376-8385.
11. Barr, M. P., Gray, S. G., Hoffmann, A. C., Hilger, R. A., Thomale, J., O'Flaherty, J. D., et al. (2013). Generation and characterisation of Cisplatin-resistant non-small cell lung cancer cell lines displaying a stem-like signature. PLoS ONE 8:e54193. doi:10.1371/journal.pone.0054193
12. Beach, S., Tang, H., Park, S., Dhillon, A. S., Keller, E. T., Kolch, W., et al. (2008). Snail is a repressor of RKIP transcription in metastatic prostate cancer cells. Oncogene 27, 2243-2248.
13. Bottero, V., Busuttil, V., Loubat, A., Magné, N., Fischel, J. L., Milano, G., et al. (2001). Activation of nuclear factor kappa B through the IKK complex by the topoisomerase poisons SN38 and doxorubicin: a brake to apoptosis in HeLa human carcinoma cells. Cancer Res. 61, 7785-7791.
14. Braeuer, S. J., Buneker, C., Mohr, A., and Zwacka, R. M. (2006). Constitutively activated nuclear factor-kappaB, but not induced NF-kappaB, leads to TRAIL resistance by up-regulation of X-linked inhibitor of apoptosis protein in human cancer cells. Mol. Cancer Res. 4, 715-728.
15. Bromberg, J. (2002). Stat proteins and oncogenesis. J. Clin. Invest. 109, 1139-1142.
16. Brown, R. E., and Law, A. (2006). Morphoproteomic demonstration of constitutive nuclear factor-kappaB activation in glioblastoma multiforme with genomic correlates and therapeutic implications. Ann. Clin. Lab. Sci. 36, 421-426.
17. Bush, J. A., Cheung, K. J. Jr., and Li, G. (2001). Curcumin induces apoptosis in human melanoma cells through a Fas receptor/caspase-8 pathway independent of p53. Exp. Cell Res. 271, 305-314.
18. Campbell, K. J., Rocha, S., and Perkins, N. D. (2004). Active repression of antiapoptotic gene expression by RelA(p65) NF-kappa B. Mol. Cell 13, 853-865.
19. Chaney, S. G., Campbell, S. L., Temple, B., Bassett, E., Wu, Y., and Faldu, M. (2004). Protein interactions with platinum-DNA adducts: from structure to function. J. Inorg. Biochem. 98, 1551-1559.
20. Chatterjee, D., Bai, Y., Wang, Z., Beach, S., Mott, S., Roy, R., et al. (2004). RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J. Biol. Chem. 279, 17515-17523.
21. Chua, H. L., Bhat-Nakshatri, P., Clare, S. E., Morimiya, A., Badve, S., and Nakshatri, H. (2007). NF-kappaB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2. Oncogene 26, 711-724.
22. Chuang, S. E., Yeh, P. Y., Lu, Y. S., Lai, G. M., Liao, C. M., Gao, M., et al. (2002). Basal levels and patterns of anticancer drug-induced activation of nuclear factor-kappaB (NF-kappaB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells. Biochem. Pharmacol. 63, 1709-1716.
23. Chung, W. H., Boo, S. H., Chung, M. K., Lee, H. S., Cho, Y. S., and Hong, S. H. (2008). Proapoptotic effects of NF-kappaB on cisplatin-induced cell death in auditory cell line. Acta Otolaryngol. 128, 1063-1070.
24. Cloughesy, T. F., Yoshimoto, K., Nghiemphu, P., Brown, K., Dang, J., Zhu, S., et al. (2008). Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 5:e8. doi:10.1371/journal.pmed.0050008
25. Croghan, G. A., Suman, V. J., Maples, W. J., Albertini, M., Linette, G., Flaherty, L., et al. (2010). A study of paclitaxel, carboplatin, and bortezomib in the treatment of metastatic malignant melanoma: a phase 2 consortium study. Cancer 116, 3463-3468.
26. Crowley, J. E., Treml, L. S., Stadanlick, J. E., Carpenter, E., and Cancro, M. P. (2005). Homeostatic niche specification among naive and activated B cells: a growing role for the BLyS family of receptors and ligands. Semin. Immunol. 17, 193-199.
27. Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., and Reed, E. (1994). Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J. Clin. Invest. 94, 703-708.
28. Darnell, J. E. Jr. (2002). Transcription factors as targets for cancer therapy. Nat. Rev. Cancer 2, 740-749.
29. Darnell, J. E. Jr., Kerr, I. M., and Stark, G. R. (1994). Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264, 1415-1421.
30. De Benedetti, A., and Graff, J. R. (2004). eIF-4E expression and its role in malignancies and metastases. Oncogene 23, 3189-3199.
31. Dhillon, N., Aggarwal, B. B., Newman, R. A., Wolff, R. A., Kunnumakkara, A. B., Abbruzzese, J. L., et al. (2008). Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res. 14, 4491-4499.
32. di Meglio, P., Ianaro, A., and Ghosh, S. (2005). Amelioration of acute inflammation by systemic administration of a cell-permeable peptide inhibitor of NF-kappaB activation. Arthritis Rheum. 52, 951-958.
33. Enzler, T., Sano, Y., Choo, M. K., Cottam, H. B., Karin, M., Tsao, H., et al. (2011). Cell-selective inhibition of NF-kappaB signaling improves therapeutic index in a melanoma chemotherapy model. Cancer Discov. 1, 496-507.
34. Epelbaum, R., Schaffer, M., Vizel, B., Badmaev, V., and Bar-Sela, G. (2010). Curcumin and gemcitabine in patients with advanced pancreatic cancer. Nutr. Cancer 62, 1137-1141.
35. Estaquier, J., Vallette, F., Vayssiere, J. L., and Mignotte, B. (2012). The mitochondrial pathways of apoptosis. Adv. Exp. Med. Biol. 942, 157-183.
36. Evan, G. I., and Vousden, K. H. (2001). Proliferation, cell cycle and apoptosis in cancer. Nature 411, 342-348.
37. Friedberg, E. C., Aguilera, A., Gellert, M., Hanawalt, P. C., Hays, J. B., Lehmann, A. R., et al. (2006). DNA repair: from molecular mechanism to human disease. DNA Repair (Amst.) 5, 986-996.
38. Fu, J., Jin, Y., and Arend, L. J. (2003). Smac3, a novel Smac/DIABLO splicing variant, attenuates the stability and apoptosis-inhibiting activity of X-linked inhibitor of apoptosis protein. J. Biol. Chem. 278, 52660-52672.
39. Fujioka, S., Schmidt, C., Sclabas, G. M., Li, Z., Pelicano, H., Peng, B., et al. (2004). Stabilization of p53 is a novel mechanism for proapoptotic function of NF-kappaB. J. Biol. Chem. 279, 27549-27559.
40. Fury, M. G., Lee, N. Y., Sherman, E., Lisa, D., Kelly, K., Lipson, B., et al. (2012). A phase 2 study of bevacizumab with cisplatin plus intensity-modulated radiation therapy for stage III/IVB head and neck squamous cell cancer. Cancer 118, 5008-5014.
41. Ghosh, S., May, M. J., and Kopp, E. B. (1998). NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu. Rev. Immunol. 16, 225-260.
42. Gibson, S. B. (2004). Epidermal growth factor and trail interactions in epithelial-derived cells. Vitam. Horm. 67, 207-227.
43. Gomez-Abuin, G., Winquist, E., Stadler, W. M., Pond, G., Degendorfer, P., Wright, J., et al. (2007). A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia. Invest. New Drugs 25, 181-185.
44. Graham, B., and Gibson, S. B. (2005). The two faces of NFkappaB in cell survival responses. Cell Cycle 4, 1342-1345.
45. Grandage, V. L., Gale, R. E., Linch, D. C., and Khwaja, A. (2005). PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kappaB, Mapkinase and p53 pathways. Leukemia 19, 586-594.
46. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 54, 4855-4878.
47. Guertin, D. A., and Sabatini, D. M. (2009). The pharmacology of mTOR inhibition. Sci. Signal. 2, e24.
48. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
49. Herbst, R. S., Heymach, J. V., and Lippman, S. M. (2008). Lung cancer. N. Engl. J. Med. 359, 1367-1380.
50. Hwang, S. G., Park, J., Park, J. Y., Park, C. H., Lee, K. H., Cho, J. W., et al. (2012). Anti-cancer activity of a novel small molecule compound that simultaneously activates p53 and inhibits NF-kappaB signaling. PLoS ONE 7:e44259. doi:10.1371/journal.pone.0044259
51. Ianaro, A., Tersigni, M., Belardo, G., Di Martino, S., Napolitano, M., Palmieri, G., et al. (2009). NEMO-binding domain peptide inhibits proliferation of human melanoma cells. Cancer Lett. 274, 331-336.
52. Inoki, K., Li, Y., Zhu, T., Wu, J., and Guan, K. L. (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4, 648-657.
53. Jennewein, C., Karl, S., Baumann, B., Micheau, O., Debatin, K. M., and Fulda, S. (2012). Identification of a novel pro-apoptotic role of NF-kappaB in the regulation of TRAIL-and CD95-mediated apoptosis of glioblastoma cells. Oncogene 31, 1468-1474.
54. Julien, S., Puig, I., Caretti, E., Bonaventure, J., Nelles, L., Van Roy, F., et al. (2007). Activation of NF-kappaB by Akt upregulates Snail expression and induces epithelium mesenchyme transition. Oncogene 26, 7445-7456.
55. Kamarajan, P., Sun, N. K., and Chao, C. C. (2003). Up-regulation of FLIP in cisplatin-selected HeLa cells causes cross-resistance to CD95/Fas death signalling. Biochem. J. 376, 253-260.
56. Kane, R. C., Farrell, A. T., Sridhara, R., and Pazdur, R. (2006). United States Food and Drug Administration approval summary: bortezomib for the treatment of progressive multiple myeloma after one prior therapy. Clin. Cancer Res. 12, 2955-2960.
57. Kartalou, M., and Essigmann, J. M. (2001). Mechanisms of resistance to cisplatin. Mutat. Res. 478, 23-43.
58. Kato, T. Jr., Delhase, M., Hoffmann, A., and Karin, M. (2003). CK2 Is a C-Terminal IkappaB Kinase Responsible for NF-kappaB Activation during the UV Response. Mol. Cell 12, 829-839.
59. Katz, M., Amit, I., and Yarden, Y. (2007). Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim. Biophys. Acta 1773, 1161-1176.
60. Kim, S. J., Hwang, S. G., Shin, D. Y., Kang, S. S., and Chun, J. S. (2002). p38 kinase regulates nitric oxide-induced apoptosis of articular chondrocytes by accumulating p53 via NFkappa B-dependent transcription and stabilization by serine 15 phosphorylation. J. Biol. Chem. 277, 33501-33508.
61. Kim, Y., Park, H., and Jeoung, D. (2009). CAGE, a cancer/testis antigen, induces c-FLIP(L) and Snail to enhance cell motility and increase resistance to an anti-cancer drug. Biotechnol. Lett. 31, 945-952.
62. Kimura, M., Haisa, M., Uetsuka, H., Takaoka, M., Ohkawa, T., Kawashima, R., et al. (2003). TNF combined with IFN-alpha accelerates NF-kappaB-mediated apoptosis through enhancement of Fas expression in colon cancer cells. Cell Death Differ. 10, 718-728.
63. Kreuz, S., Siegmund, D., Scheurich, P., and Wajant, H. (2001). NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling. Mol. Cell. Biol. 21, 3964-3973.
64. Kuhnel, F., Zender, L., Paul, Y., Tietze, M. K., Trautwein, C., Manns, M., et al. (2000). NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J. Biol. Chem. 275, 6421-6427.
65. Kulesza, D. W., Carre, T., Chouaib, S., and Kaminska, B. (2013). Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFalpha-and NK cytotoxicity. Exp. Cell Res. 319, 506-516.
66. Kuroda, H., Takeno, M., Murakami, S., Miyazawa, N., Kaneko, T., and Ishigatsubo, Y. (2010). Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cells. Lung Cancer 67, 31-36.
67. Lai, S. L., Perng, R. P., and Hwang, J. (2000). p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells. J. Biomed. Sci. 7, 64-70.
68. Lao, C. D., Ruffin, M. T. T., Normolle, D., Heath, D. D., Murray, S. I., Bailey, J. M., et al. (2006). Dose escalation of a curcuminoid formulation. BMC Complement. Altern. Med. 6:10. doi:10.1186/1472-6882-6-10
69. Lee, H., Herrmann, A., Deng, J. H., Kujawski, M., Niu, G., Li, Z., et al. (2009). Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 15, 283-293.
70. Lee, S., Yoon, C. Y., Byun, S. S., Lee, E., and Lee, S. E. (2013). The Role of c-FLIP in Cisplatin Resistance of Human Bladder Cancer Cells. J. Urol. 189, 2329-2336.
71. Li, Q., and Verma, I. M. (2002). NF-kappaB regulation in the immune system. Nat. Rev. Immunol. 2, 725-734.
72. Li, Y., Ahmed, F., Ali, S., Philip, P. A., Kucuk, O., and Sarkar, F. H. (2005a). Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res. 65, 6934-6942.
73. Li, Z., Niu, J., Uwagawa, T., Peng, B., and Chiao, P. J. (2005b). Function of polo-like kinase 3 in NF-kappaB-mediated proapoptotic response. J. Biol. Chem. 280, 16843-16850.
74. Lin, B., Williams-Skipp, C., Tao, Y., Schleicher, M. S., Cano, L. L., Duke, R. C., et al. (1999). NF-kappaB functions as both a proapoptotic and antiapoptotic regulatory factor within a single cell type. Cell Death Differ. 6, 570-582.
75. Lomonaco, S. L., Xu, X. S., and Wang, G. (2009). The role of Bcl-x(L) protein in nucleotide excision repair-facilitated cell protection against cisplatin-induced apoptosis. DNA Cell Biol. 28, 285-294.
76. Longley, D. B., Wilson, T. R., McEwan, M., Allen, W. L., McDermott, U., Galligan, L., et al. (2006). c-FLIP inhibits chemotherapy-induced colorectal cancer cell death. Oncogene 25, 838-848.
77. Lu, Z. H., Shvartsman, M. B., Lee, A. Y., Shao, J. M., Murray, M. M., Kladney, R. D., et al. (2010). Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis. Cancer Res. 70, 3287-3298.
78. Luo, A., Wang, W., Sima, N., Lu, Y., Zhou, J., Xu, G., et al. (2008). Short hairpin RNA targeting c-FLIP sensitizes human cervical adenocarcinoma Hela cells to chemotherapy and radiotherapy. Cancer Lett. 271, 323-332.
79. MacFarlane, M., Jones, N. A., Dive, C., and Cohen, G. M. (1996). DNA-damaging agents induce both p53-dependent and p53-independent apoptosis in immature thymocytes. Mol. Pharmacol. 50, 900-911.
80. Meric-Bernstam, F., and Gonzalez-Angulo, A. M. (2009). Targeting the mTOR signaling network for cancer therapy. J. Clin. Oncol. 27, 2278-2287.
81. Meylan, E., Dooley, A. L., Feldser, D. M., Shen, L., Turk, E., Ouyang, C., et al. (2009). Requirement for NF-kappaB signalling in a mouse model of lung adenocarcinoma. Nature 462, 104-107.
82. Micheau, O., Lens, S., Gaide, O., Alevizopoulos, K., and Tschopp, J. (2001). NF-kappaB signals induce the expression of c-FLIP. Mol. Cell. Biol. 21, 5299-5305.
83. Micheau, O., Solary, E., Hammann, A., and Dimanche-Boitrel, M. T. (1999). Fas ligand-independent, FADD-mediated activation of the Fas death pathway by anticancer drugs. J. Biol. Chem. 274, 7987-7992.
84. Miller, S. C., Huang, R., Sakamuru, S., Shukla, S. J., Attene-Ramos, M. S., Shinn, P., et al. (2010). Identification of known drugs that act as inhibitors of NF-kappaB signaling and their mechanism of action. Biochem. Pharmacol. 79, 1272-1280.
85. Miyamoto, S. (2004). RelA life and death decisions. Mol. Cell 13, 763-764.
86. Mora, E., Guglielmotti, A., Biondi, G., and Sassone-Corsi, P. (2012). Bindarit: an anti-inflammatory small molecule that modulates the NFkappaB pathway. Cell Cycle 11, 159-169.
87. Nakanishi, C., and Toi, M. (2005). Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 5, 297-309.
88. Namba, R., Young, L. J., Abbey, C. K., Kim, L., Damonte, P., Borowsky, A. D., et al. (2006). Rapamycin inhibits growth of premalignant and malignant mammary lesions in a mouse model of ductal carcinoma in situ. Clin. Cancer Res. 12, 2613-2621.
89. Nicholson, R. I., Gee, J. M., and Harper, M. E. (2001). EGFR and cancer prognosis. Eur. J. Cancer 37(Suppl. 4), S9-15.
90. Nomura, T., Yamasaki, M., Nomura, Y., and Mimata, H. (2005). Expression of the inhibitors of apoptosis proteins in cisplatin-resistant prostate cancer cells. Oncol. Rep. 14, 993-997.
91. Non-aka, M., Itamochi, H., Kawaguchi, W., Kudoh, A., Sato, S., Uegaki, K., et al. (2012). Activation of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase pathway overcomes cisplatin resistance in ovarian carcinoma cells. Int. J. Gynecol. Cancer 22, 922-929.
92. Odot, J., Albert, P., Carlier, A., Tarpin, M., Devy, J., and Madoulet, C. (2004). In vitro and in vivo anti-tumoral effect of curcumin against melanoma cells. Int J Cancer 111, 381-387.
93. Oliver, T. G., Mercer, K. L., Sayles, L. C., Burke, J. R., Mendus, D., Lovejoy, K. S., et al. (2010). Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. Genes Dev. 24, 837-852.
94. Pahl, H. L. (1999). Activators and target genes of Rel/NF-kappaB transcription factors. Oncogene 18, 6853-6866.
95. Patel, N. M., Nozaki, S., Shortle, N. H., Bhat-Nakshatri, P., Newton, T. R., Rice, S., et al. (2000). Paclitaxel sensitivity of breast cancer cells with constitutively active NF-kappa B is enhanced by I kappa B alpha super-repressor and parthenolide. Oncogene 19, 4159-4169.
96. Pikarsky, E., and Ben-Neriah, Y. (2006). NF-kappaB inhibition: a double-edged sword in cancer? Eur. J. Cancer 42, 779-784.
97. Radhakrishnan, S. K., and Kamalakaran, S. (2006). Pro-apoptotic role of NF-kappaB: implications for cancer therapy. Biochim. Biophys. Acta 1766, 53-62.
98. Rae, C., Langa, S., Tucker, S. J., and Macewan, D. J. (2007). Elevated NF-kappaB responses and FLIP levels in leukemic but not normal lymphocytes: reduction by salicylate allows TNF-induced apoptosis. Proc. Natl. Acad. Sci. U.S.A. 104, 12790-12795.
99. Ravi, R., Bedi, G. C., Engstrom, L. W., Zeng, Q., Mookerjee, B., Gelinas, C., et al. (2001). Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB. Nat. Cell Biol. 3, 409-416.
100. Reuter, S., Eifes, S., Dicato, M., Aggarwal, B. B., and Diederich, M. (2008). Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem. Pharmacol. 76, 1340-1351.
101. Ricca, A., Biroccio, A., Trisciuoglio, D., Cippitelli, M., Zupi, G., and Del Bufalo, D. (2001). relA over-expression reduces tumorigenicity and activates apoptosis in human cancer cells. Br. J. Cancer 85, 1914-1921.
102. Rivera-Walsh, I., Waterfield, M., Xiao, G., Fong, A., and Sun, S. C. (2001). NF-kappaB signaling pathway governs TRAIL gene expression and human T-cell leukemia virus-I Tax-induced T-cell death. J. Biol. Chem. 276, 40385-40388.
103. Rogers, K. M., Thomas, M., Galligan, L., Wilson, T. R., Allen, W. L., Sakai, H., et al. (2007). Cellular FLICE-inhibitory protein regulates chemotherapy-induced apoptosis in breast cancer cells. Mol. Cancer Ther. 6, 1544-1551.
104. Ryan, K. M., Ernst, M. K., Rice, N. R., and Vousden, K. H. (2000). Role of NF-kappaB in p53-mediated programmed cell death. Nature 404, 892-897.
105. Sanchez-Perez, I., Benitah, S. A., Martinez-Gomariz, M., Lacal, J. C., and Perona, R. (2002). Cell stress and MEKK1-mediated c-Jun activation modulate NFkappaB activity and cell viability. Mol. Biol. Cell 13, 2933-2945.
106. Sarbassov, D. D., Guertin, D. A., Ali, S. M., and Sabatini, D. M. (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101.
107. Silke, J., Kratina, T., Chu, D., Ekert, P. G., Day, C. L., Pakusch, M., et al. (2005). Determination of cell survival by RING-mediated regulation of inhibitor of apoptosis (IAP) protein abundance. Proc. Natl. Acad. Sci. U.S.A. 102, 16182-16187.
108. Takeuchi, H., Kim, J., Fujimoto, A., Umetani, N., Mori, T., Bilchik, A., et al. (2005). X-Linked inhibitor of apoptosis protein expression level in colorectal cancer is regulated by hepatocyte growth factor/C-met pathway via Akt signaling. Clin. Cancer Res. 11, 7621-7628.
109. Tan, C., and Waldmann, T. A. (2002). Proteasome inhibitor PS-341, a potential therapeutic agent for adult T-cell leukemia. Cancer Res. 62, 1083-1086.
110. Tanaka, K., Babic, I., Nathanson, D., Akhavan, D., Guo, D., Gini, B., et al. (2011). Oncogenic EGFR signaling activates an mTORC2-NF-kappaB pathway that promotes chemotherapy resistance. Cancer Discov. 1, 524-538.
111. Tew, G. W., Lorimer, E. L., Berg, T. J., Zhi, H., Li, R., and Williams, C. L. (2008). SmgGDS regulates cell proliferation, migration, and NF-kappaB transcriptional activity in non-small cell lung carcinoma. J. Biol. Chem. 283, 963-976.
112. Thevenod, F., Friedmann, J. M., Katsen, A. D., and Hauser, I. A. (2000). Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappa B activation protects kidney proximal tubule cells from cadmium-and reactive oxygen species-induced apoptosis. J. Biol. Chem. 275, 1887-1896.
113. Umezawa, K. (2006). Inhibition of tumor growth by NF-kappaB inhibitors. Cancer Sci. 97, 990-995.
114. Umezawa, K., and Chaicharoenpong, C. (2002). Molecular design and biological activities of NF-kappaB inhibitors. Mol. Cells 14, 163-167.
115. Vilimas, T., Mascarenhas, J., Palomero, T., Mandal, M., Buonamici, S., Meng, F., et al. (2007). Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. Nat. Med. 13, 70-77.
116. Voortman, J., Smit, E. F., Honeywell, R., Kuenen, B. C., Peters, G. J., Van De Velde, H., et al. (2007). A parallel dose-escalation study of weekly and twice-weekly bortezomib in combination with gemcitabine and cisplatin in the first-line treatment of patients with advanced solid tumors. Clin. Cancer Res. 13, 3642-3651.
117. Wang, C. Y., Guttridge, D. C., Mayo, M. W., and Baldwin, A. S. Jr. (1999). NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol. Cell. Biol. 19, 5923-5929.
118. Wang, C. Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., and Baldwin, A. S. Jr. (1998). NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281, 1680-1683.
119. Wang, Y., Cui, H., Schroering, A., Ding, J. L., Lane, W. S., Mcgill, G., et al. (2002). NF-kappa B2 p100 is a pro-apoptotic protein with anti-oncogenic function. Nat. Cell Biol. 4, 888-893.
120. Weinstein, I. B. (2002). Cancer. Addiction to oncogenes-the Achilles heal of cancer. Science 297, 63-64.
121. Wilson, C., Wilson, T., Johnston, P. G., Longley, D. B., and Waugh, D. J. (2008). Interleukin-8 signaling attenuates TRAIL-and chemotherapy-induced apoptosis through transcriptional regulation of c-FLIP in prostate cancer cells. Mol. Cancer Ther. 7, 2649-2661.
122. Wu, Z. H., and Miyamoto, S. (2008). Induction of a pro-apoptotic ATM-NF-kappaB pathway and its repression by ATR in response to replication stress. EMBO J. 27, 1963-1973.
123. Wuerzberger-Davis, S. M., Nakamura, Y., Seufzer, B. J., and Miyamoto, S. (2007). NF-kappaB activation by combinations of NEMO SUMOylation and ATM activation stresses in the absence of DNA damage. Oncogene 26, 641-651.
124. Yang, C. H., Gonzalez-Angulo, A. M., Reuben, J. M., Booser, D. J., Pusztai, L., Krishnamurthy, S., et al. (2006a). Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann. Oncol. 17, 813-817.
125. Yang, J., Amiri, K. I., Burke, J. R., Schmid, J. A., and Richmond, A. (2006b). BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways. Clin. Cancer Res. 12, 950-960.
126. Yang, G., Xiao, X., Rosen, D. G., Cheng, X., Wu, X., Chang, B., et al. (2011). The biphasic role of NF-kappaB in progression and chemoresistance of ovarian cancer. Clin. Cancer Res. 17, 2181-2194.
127. Yang, J., Liao, X., Agarwal, M. K., Barnes, L., Auron, P. E., and Stark, G. R. (2007). Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 21, 1396-1408.
128. Yang, X. H., Feng, Z. E., Yan, M., Hanada, S., Zuo, H., Yang, C. Z., et al. (2012). XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer. PLoS ONE 7:e31601. doi:10.1371/journal.pone.0031601
129. Yeung, K., Seitz, T., Li, S., Janosch, P., Mcferran, B., Kaiser, C., et al. (1999). Suppression of Raf-1 kinase activity and MAP kinase signalling by RKIP. Nature 401, 173-177.
130. Yeung, K. C., Rose, D. W., Dhillon, A. S., Yaros, D., Gustafsson, M., Chatterjee, D., et al. (2001). Raf kinase inhibitor protein interacts with NF-kappaB-inducing kinase and TAK1 and inhibits NF-kappaB activation. Mol. Cell. Biol. 21, 7207-7217.
131. Zinzalla, V., Stracka, D., Oppliger, W., and Hall, M. N. (2011). Activation of mTORC2 by association with the ribosome. Cell 144, 757-768.
132. Zollo, M., Di Dato, V., Spano, D., De Martino, D., Liguori, L., Marino, N., et al. (2012). Targeting monocyte chemotactic protein-1 synthesis with bindarit induces tumor regression in prostate and breast cancer animal models. Clin. Exp. Metastasis 29, 585-601.
133. Zou, P., Kawada, J., Pesnicak, L., and Cohen, J. I. (2007). Bortezomib induces apoptosis of Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with EBV-transformed B cells. J. Virol. 81, 10029-10036.